Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
MarketWatch · Fri, 06 Nov 2026 16:29:00 GMT
Read the full story at MarketWatch ↗OmniFin Portal's take
Excerpt from MarketWatch: “As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.”
Rule-based headline sentiment: Bullish
More Stocks headlines
‘It feels like he’s quietly building a separate life’: My husband inherited $500,000, but he refuses to spend it on our home— MarketWatchOpenAI bugging suspect Alfozan pleads not guilty— CNBC MarketsTrump says Stephen Miller to replace Susie Wiles as White House chief of staff— CNBC MarketsMy 93-year-old father changed his will at the 11th hour, leaving my brother his entire $500,000 estate. Can I challenge it?— MarketWatch
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →